Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging

Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls

(2021) Enrique Alvarez et al.   Multiple Sclerosis and Related Disorders

MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice

(2020) Jaume Sastre-Garriga et al.   Nature Reviews Neurology

Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis

(2020) Madeline Bross et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Lesion activity and chronic demyelination are the major determinants of brain atrophy in MS

(2019) Chenyu Wang et al.   Neurology-Neuroimmunology & Neuroinflammation

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis

(2019) Colm Elliott et al.   BRAIN

Contribution of normal aging to brain atrophy in MS

(2019) Christina J. Azevedo et al.   Neurology-Neuroimmunology & Neuroinflammation

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions

(2018) Colm Elliott et al.   Multiple Sclerosis Journal

Pathological cut-offs of global and regional brain volume loss in multiple sclerosis

(2017) Tomas Uher et al.   Multiple Sclerosis Journal

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pathological cut-offs of global and regional brain volume loss in multiple sclerosis

(2017) Tomas Uher et al.   Multiple Sclerosis Journal

Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis

(2016) Hyunwoo Lee et al.   Multiple Sclerosis Journal

Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis

(2016) Hyunwoo Lee et al.   Multiple Sclerosis Journal

Fitting Linear Mixed-Effects Models Usinglme4

(2015) Douglas Bates et al.   Journal of Statistical Software

Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study

(2014) Douglas L. Arnold et al.   JOURNAL OF NEUROLOGY

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial

(2013) Douglas L. Arnold et al.   JOURNAL OF NEUROLOGY

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

(2013) Christian Klein et al.   mAbs

Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis

(2013) Kunio Nakamura et al.   NeuroImage-Clinical

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Multiple Sclerosis: An Immune or Neurodegenerative Disorder?

(2008) Bruce D. Trapp et al.   Annual Review of Neuroscience